ArticleJournal of virology2003
Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 68 citations in OpenAlex.
- Engineered mesenchymal stem/stromal cells against cancer.Cell death & disease · 2025Review
- Preferential expression of SCN1A in GABAergic neurons improves survival and epileptic phenotype in a mouse model of Dravet syndrome.Journal of molecular medicine (Berlin, Germany) · 2023Article
- Pathogenicity and virulence of human adenovirus F41: Possible links to severe hepatitis in children.Virulence · 2023Review
- IgG Fc Affinity Ligands and Their Applications in Antibody-Involved Drug Delivery: A Brief Review.Pharmaceutics · 2023Review
- Review
- Review
- Construction of a pIX-modified Adenovirus Vector Able to Effectively Bind to Nanoantibodies for Targeting.Acta naturae · 2014Article
- Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Targeting of liposomes via PSGL1 for enhanced tumor accumulation.Pharmaceutical research · 2013Article
- Mannan-modified Ad5-PTEN treatment combined with docetaxel improves the therapeutic effect in H22 tumor-bearing mice.International journal of nanomedicine · 2012Article
- Article
- Resistance of canine lymphoma cells to adenoviral infection due to reduced cell surface RGD binding integrins.Cancer biology & therapy · 2011Article
- Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins.Journal of controlled release : official journal of the Controlled Release Society · 2011Article
- Her2-specific multivalent adapters confer designed tropism to adenovirus for gene targeting.Journal of molecular biology · 2011Article
- Article
- Development of a targeted gene vector platform based on simian adenovirus serotype 24.Journal of virology · 2010Article
- Article
- Assembly of hybrid bacteriophage Qbeta virus-like particles.Biochemistry · 2009Article
- Article
- Improved adenovirus type 5 vector-mediated transduction of resistant cells by piggybacking on coxsackie B-adenovirus receptor-pseudotyped baculovirus.Journal of virology · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
Abstract
A potential barrier to the development of genetically targeted adenovirus (Ad) vectors for cell-specific delivery of gene therapeutics lies in the fact that several types of targeting protein ligands require posttranslational modifications, such as the formation of disulfide bonds, which are not available to Ad capsid proteins due to their nuclear localization during assembly of the virion. To overcome this problem, we developed a new targeting strategy, which combines genetic modifications of the Ad capsid with a protein bridge approach, resulting in a vector-ligand targeting complex. The components of the complex associate by virtue of genetic modifications to both the Ad capsid and the targeting ligand. One component of this mechanism of association, the Fc-binding domain of Staphylococcus aureus protein A, is genetically incorporated into the Ad fiber protein. The ligand is comprised of a targeting component fused with the Fc domain of immunoglobulin, which serves as a docking moiety to bind to these genetically modified fibers during the formation of the Ad-ligand complex. The modular design of the ligand solves the problem of structural and biosynthetic compatibility with the Ad and thus facilitates targeting of the vector to a variety of cellular receptors. Our study shows that targeting ligands incorporating the Fc domain and either an anti-CD40 single-chain antibody or CD40L form stable complexes with protein A-modified Ad vectors, resulting in significant augmentation of gene delivery to CD40-positive target cells. Since this gene transfer is independent of the expression of the native Ad5 receptor by the target cells, this strategy results in the derivation of truly targeted Ad vectors suitable for tissue-specific gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.